此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier Repair

2026年11月4日 更新者:L'Oreal

A Single-Center, Double-Blinded, Randomized, Placebo-Controlled, Prospective Study to Evaluate the Efficacy and Safety of a Botanical Extract in Skincare Formulations for Skin Barrier Repair on Healthy Volunteers

This is a single-center, double-blinded, placebo-controlled, prospective clinical study designed to evaluate the skin barrier repair efficacy and local tolerance of topical cosmetic formulations containing a botanical extract. Skin barrier challenge is induced via standardized tape stripping on the volar forearm of healthy subjects. The study will evaluate and compare the repair kinetics of two concentrations of the active formulation, a vehicle, and an untreated control zone over a 14-day application period.

研究概览

详细说明

Healthy female subjects will undergo a standardized skin barrier challenge (tape-stripping) on designated zones of their volar forearms at baseline. Formulations containing different concentrations of a botanical extract (Active Formulation A and Active Formulation B), a vehicle control, and an untreated control will be assigned to the randomized zones. Products will be applied topically twice daily for 14 days. Skin barrier repair efficacy will be assessed using clinical gradings and instrumental measurements, including Trans-Epidermal Water Loss (TEWL) and skin hydration. Local tolerance will be evaluated via clinical grading. Non-invasive skin surface biomaterial collection may be performed at designated time points for skin proteomics and lipidomics analysis.

研究类型

介入性

注册 (实际的)

35

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Shanghai、中国
        • L'OREAL

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

35年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  1. Chinese women aged 35 to 60 years in good general health.
  2. Self-reported dry skin type.
  3. a hydration index < 35 and a trans-epidermal water loss (TEWL) ≥ 6g.m-2.h-1 on both anterior sides of the forearms at screening.
  4. Willingness to avoid excessive sun exposure and comply with all study procedures including tape stripping and biosampling.
  5. Bilateral forearms clear of scars, wounds, or significant pigment spots.

Exclusion Criteria:

  1. Current pregnancy, breastfeeding, or planning to become pregnant.
  2. Current smokers or history of smoking within the last 6 months (including e-cigarettes/nicotine products).
  3. History of facial cosmetic procedures (fillers, lasers, implants, Botox, etc.).
  4. Active systemic or localized skin diseases (acne, eczema, psoriasis, atopic dermatitis).
  5. Allergies to cosmetics, personal care products, or their ingredients.
  6. Excessive UV exposure or frequent sauna/water sports usage.
  7. Use of antihistamines, antibiotics, corticosteroids, or NSAIDs within the relevant washout periods.
  8. Participation in any other clinical trial within the past 30 days.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Active Formulation A

Zones applying 0.24% active formulation

Topical skincare formulation containing Botanical Extract (Concentration A). Applied twice daily for 14 days.

实验性的:Active Formulation B

Zones applying 0.05% active formulation

Topical skincare formulation containing Botanical Extract (Concentration B). Applied twice daily for 14 days.

安慰剂比较:Vehicle Control

Zones applying the formulation base without active extract

Topical formulation base (identical to investigational products but without the active botanical extract). Applied twice daily for 14 days.

无干预:Untreated Zone

Control Zone on the forearm with no product application: Tape stripped zone left untreated to monitor natural physiological repairing kinetics

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Clinical Scoring (Erythema, Dryness, Desquamation, Roughness, Edema, PIH)
大体时间:Baseline, Tafter (immediately after tape stripping), T3h (3 hours after 1st product application), Day 1, Day 3, Day 7, and Day 14

Dermatological grading of erythema, dryness, roughness, edema, desquamation and post-inflammatory hyperpigmentation using standard clinical scales

Baseline, Tafter (immediately after tape stripping), T3h (3 hours after 1st product application), Day 1, Day 3, Day 7, and Day 14
Hydration
大体时间:Baseline, Tafter (right after tape stripping), Timm (immediately after 1st product application), T1h(1 hour after 1st product application), T3h(3 hours after 1st product application), Day 1, Day 3, Day 7, and Day 14

Hydration index measured using Corneometer

Baseline, Tafter (right after tape stripping), Timm (immediately after 1st product application), T1h(1 hour after 1st product application), T3h(3 hours after 1st product application), Day 1, Day 3, Day 7, and Day 14
TEWL
大体时间:Baseline, post-stripping (Tafter), immediately post-first application (Timm), 1 hour post-first application (T1h), 3 hours post-first application (T3h), Day 1, Day 3, Day 7, and Day 14.

Trans-epidermal water loss using Vapometer

Baseline, post-stripping (Tafter), immediately post-first application (Timm), 1 hour post-first application (T1h), 3 hours post-first application (T3h), Day 1, Day 3, Day 7, and Day 14.

次要结果测量

结果测量
措施说明
大体时间
Skin Structural Changes
大体时间:Baseline, Day 3, Day 7, and Day 14

Non-invasive evaluation of epidermis and dermis thickness/density using high-frequency ultrasound

Baseline, Day 3, Day 7, and Day 14
Epidermal Proteomic and Lipidomic Profile
大体时间:Baseline, Day 7

Characterization of stratum corneum biomarkers obtained via non-invasive tape-stripping samplings.

Baseline, Day 7

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年10月13日

初级完成 (实际的)

2025年11月3日

研究完成 (实际的)

2026年7月25日

研究注册日期

首次提交

2026年6月9日

首先提交符合 QC 标准的

2026年6月9日

首次发布 (实际的)

2026年6月12日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • ACR_EV_25-11289

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅